JP2024504645A - 放射線誘発性疾患を予防、改善、又は軽減するプテロスチルベン及びシリビニン - Google Patents

放射線誘発性疾患を予防、改善、又は軽減するプテロスチルベン及びシリビニン Download PDF

Info

Publication number
JP2024504645A
JP2024504645A JP2023542925A JP2023542925A JP2024504645A JP 2024504645 A JP2024504645 A JP 2024504645A JP 2023542925 A JP2023542925 A JP 2023542925A JP 2023542925 A JP2023542925 A JP 2023542925A JP 2024504645 A JP2024504645 A JP 2024504645A
Authority
JP
Japan
Prior art keywords
pterostilbene
salt
silibinin
radiation
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023542925A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024504645A5 (enExample
Inventor
アリギュエル ホセ マリア エストレラ
プラ マリア エレナ オブラドール
パーマー マリア ロサリオ サルヴァドール
パストル アレグリア モントーロ
Original Assignee
ウニベルシタ デ バレンシア
インスティテュート デ インベスティガシオン サニタリア ラ フェ－フンダシオン パラ ラ インベスティガシオン デル ホスピタル ウニベルシタリオ イ ポリテクニコ ラ フェ デ ラ コミュニダ バレンシアナ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ウニベルシタ デ バレンシア, インスティテュート デ インベスティガシオン サニタリア ラ フェ－フンダシオン パラ ラ インベスティガシオン デル ホスピタル ウニベルシタリオ イ ポリテクニコ ラ フェ デ ラ コミュニダ バレンシアナ filed Critical ウニベルシタ デ バレンシア
Publication of JP2024504645A publication Critical patent/JP2024504645A/ja
Publication of JP2024504645A5 publication Critical patent/JP2024504645A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/34—Alcohols
    • A61K8/347—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
    • A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/60—Sugars; Derivatives thereof
    • A61K8/602—Glycosides, e.g. rutin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2250/00—Food ingredients
    • A23V2250/30—Other Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Birds (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
JP2023542925A 2021-01-18 2022-01-18 放射線誘発性疾患を予防、改善、又は軽減するプテロスチルベン及びシリビニン Pending JP2024504645A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21382036.8A EP4029496A1 (en) 2021-01-18 2021-01-18 Pterostilbene and silibinin for preventing, ameliorating or reducing radiation-induced diseases
EP21382036.8 2021-01-18
PCT/EP2022/051038 WO2022152943A1 (en) 2021-01-18 2022-01-18 Pterostilbene and silibinin for preventing, ameliorating or reducing radiation-induced diseases

Publications (2)

Publication Number Publication Date
JP2024504645A true JP2024504645A (ja) 2024-02-01
JP2024504645A5 JP2024504645A5 (enExample) 2025-01-28

Family

ID=74205784

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023542925A Pending JP2024504645A (ja) 2021-01-18 2022-01-18 放射線誘発性疾患を予防、改善、又は軽減するプテロスチルベン及びシリビニン

Country Status (11)

Country Link
US (1) US20250275940A1 (enExample)
EP (2) EP4029496A1 (enExample)
JP (1) JP2024504645A (enExample)
KR (1) KR20230135110A (enExample)
CN (1) CN117202900A (enExample)
AU (1) AU2022207675A1 (enExample)
CA (1) CA3207734A1 (enExample)
ES (1) ES3029832T3 (enExample)
MX (1) MX2023008447A (enExample)
PL (1) PL4277610T3 (enExample)
WO (1) WO2022152943A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115969741B (zh) * 2023-02-21 2025-02-11 水羊化妆品制造有限公司 小花茉莉花蜡和/或小花茉莉净油组合物及应用
JP7799975B2 (ja) * 2023-03-29 2026-01-16 株式会社大阪ソーダ 皮膚バリヤ機能改善剤、及び肌状態改善剤
EP4541351A1 (en) * 2023-10-18 2025-04-23 Center for Intelligent Research in Crystal Engineering, S.L. Compounds and combination as stimulators of collagen synthesis

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004091397A (ja) * 2002-08-30 2004-03-25 Fancl Corp 表皮の偏平化を予防、防止、改善する皮膚老化防止用組成物
JP2006265186A (ja) * 2005-03-24 2006-10-05 Fancl Corp シリマリン含有光老化防止剤キット
WO2014151891A1 (en) * 2013-03-14 2014-09-25 Walley Darlene Topical products
JP2016538271A (ja) * 2013-10-30 2016-12-08 クロマデックス, インコーポレイテッドChromaDex, Inc. 皮膚症状の治療において局所使用されるニコチンアミドリボシド組成物
JP2017525738A (ja) * 2014-09-04 2017-09-07 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 皮膚におけるバリア機能のｕｖ誘導性喪失の処置に使用される局所プテロスチルベン組成物
JP2019524856A (ja) * 2016-08-22 2019-09-05 エリジウム・ヘルス・インコーポレイテッド ニコチンアミドリボシド及びプテロスチルベン組成物及び神経変性障害の治療方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9050284B2 (en) * 2009-02-09 2015-06-09 Sami Labs Limited Orally bioavailable stilbenoids—compositions and therapeutic applications thereof
US20110136751A1 (en) * 2009-10-06 2011-06-09 Green Molecular Use of Polyphenols in the Treatment of Cancer
FR2961814B1 (fr) * 2010-06-29 2014-09-26 Isp Investments Inc Nouveaux peptides activateurs de la sirtuine 6 et composition cosmetique ou pharmaceutiques les comprenant.
MX2014003606A (es) * 2011-09-27 2015-01-16 Univ Virginia Commonwealth Enfoque metabolico selectivo para aumentar la biodisponibilidad oral de la fenilefrina y otros bioactivos metabolicos.
WO2014112194A1 (ja) * 2013-01-21 2014-07-24 富士フイルム株式会社 油性組成物、並びにそれを含むエマルション組成物及び皮膚外用組成物
WO2014168925A1 (en) * 2013-04-08 2014-10-16 Virginia Commonwealth University Compositions to alleviate presystemic metabolism of opioids
CA3021022C (en) * 2016-04-14 2024-04-23 ChromaDex Inc. Use of nicotinamide riboside, nicotinic acid riboside, nicotinamide mononucleotide, and nicotinoyl compound derivatives in infant formula
CN109419634B (zh) * 2017-08-31 2023-01-31 富士胶片株式会社 水包油型乳化组合物以及皮肤外用剂
CN108478479A (zh) * 2018-04-02 2018-09-04 青岛科技大学 含有能自行提供弱酸性环境的紫檀芪复合物的眼部抗皱啫喱及其制备方法

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004091397A (ja) * 2002-08-30 2004-03-25 Fancl Corp 表皮の偏平化を予防、防止、改善する皮膚老化防止用組成物
JP2006265186A (ja) * 2005-03-24 2006-10-05 Fancl Corp シリマリン含有光老化防止剤キット
WO2014151891A1 (en) * 2013-03-14 2014-09-25 Walley Darlene Topical products
JP2016538271A (ja) * 2013-10-30 2016-12-08 クロマデックス, インコーポレイテッドChromaDex, Inc. 皮膚症状の治療において局所使用されるニコチンアミドリボシド組成物
JP2017525738A (ja) * 2014-09-04 2017-09-07 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 皮膚におけるバリア機能のｕｖ誘導性喪失の処置に使用される局所プテロスチルベン組成物
JP2019524856A (ja) * 2016-08-22 2019-09-05 エリジウム・ヘルス・インコーポレイテッド ニコチンアミドリボシド及びプテロスチルベン組成物及び神経変性障害の治療方法

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CATHRYN J. KURKJIAN ET AL.: "The TollLike Receptor 2/6 Agonist, FSL1 Lipopeptide, Therapeutically Mitigates Acute Radiation Syndr", SCIENTIFIC REPORTS, vol. 7, no. 1, JPN6025053902, 11 December 2017 (2017-12-11), ISSN: 0005765757 *
CHAO SONG ET AL.: "Sodium fluoride induces nephrotoxicity via oxidative stress-regulated mitochondrial SIRT3 signaling", SCIENTIFIC REPORTS, vol. 7, no. 1, JPN6025053904, 6 April 2017 (2017-04-06), ISSN: 0005765755 *
NICOLAS FISCHER ET AL.: "Prevention from radiation damage by natural products", PHYTOMEDICINE, vol. 47, JPN6025053903, August 2018 (2018-08-01), pages 192 - 200, ISSN: 0005765756 *

Also Published As

Publication number Publication date
CN117202900A (zh) 2023-12-08
EP4277610C0 (en) 2025-02-26
ES3029832T3 (en) 2025-06-25
WO2022152943A1 (en) 2022-07-21
PL4277610T3 (pl) 2025-08-18
MX2023008447A (es) 2023-10-09
EP4029496A1 (en) 2022-07-20
EP4277610A1 (en) 2023-11-22
CA3207734A1 (en) 2022-07-21
AU2022207675A1 (en) 2023-08-17
EP4277610B1 (en) 2025-02-26
KR20230135110A (ko) 2023-09-22
US20250275940A1 (en) 2025-09-04

Similar Documents

Publication Publication Date Title
Ren et al. Resveratrol: molecular mechanisms, health benefits, and potential adverse effects
Turrini et al. Potential effects of pomegranate polyphenols in cancer prevention and therapy
Mangla et al. Sulforaphane: A review of its therapeutic potentials, advances in its nanodelivery, recent patents, and clinical trials
JP5785569B2 (ja) がんの治療におけるフィトカンナビノイド
Kim et al. Epigenetic modifications of triterpenoid ursolic acid in activating Nrf2 and blocking cellular transformation of mouse epidermal cells
EP4277610B1 (en) Pterostilbene and silibinin for preventing, ameliorating or reducing radiation-induced diseases
Tiwari et al. Silibinin in cancer therapy: A promising prospect
US20230025435A1 (en) Compositions and methods for increasing cellular vitality and longevity and decreasing molecular ageing
US20250090490A1 (en) Compositions of Azadirachta Indica and Methods of Treating Cancer
Kowsari et al. Resveratrol in cancer treatment with a focus on breast cancer
Kaur et al. Targeting Peroxisome Proliferator-Activated Receptor-β/δ, Reactive Oxygen Species and Redox Signaling with Phytocompounds for Cancer Therapy
Poortalebi et al. Therapeutic Effect of Resveratrol and its Novel Formulations on Lung Cancer: Focus on Biological Aspects and Underlying Pathways
Wuputra et al. Therapeutic Potential of Resveratrol in Cancer and Neurodegenerative Disorders: A Current Review
Mukherjee et al. Bioactive flavonoid apigenin and its nanoformulations: a promising hope for diabetes and cancer
HK40104200B (en) Pterostilbene and silibinin for preventing, ameliorating or reducing radiation-induced diseases
HK40104200A (en) Pterostilbene and silibinin for preventing, ameliorating or reducing radiation-induced diseases
Akça et al. Autophagic mechanisms in longevity intervention: role of natural active compounds
Rodríguez González et al. Punica granatum L. constituents for cancer prevention, chemosensitisation and therapeutic treatment
Sehrawat et al. Scientific evidence for anticancer effects of Withania somnifera and its primary bioactive component withaferin A
Farhan et al. Current Understanding of Flavonoids in Cancer Therapy and Prevention. Metabolites 2023, 13, 481
Sharma et al. 8 Role of Resveratrol in Molecular Targeting
Vallianou et al. Foods and nutrients as adjuvants in cancer chemo-prevention and treatment
Peter et al. A combination of a natural polyphenol curcumin and glucose analog inhibits multiple cancer hallmarks in grade-IV glioma model
Kadannagari Elucidate the Neuro-Pharmacodynamic Actions of 3-Hydroxypterostilbene
Tannock et al. Influence of concurrent medications on outcomes of men with prostate cancer included in the TAX 327 study

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20230908

RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20230908

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250120

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250120

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20251226

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260106

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260402